About bit.bio
bit.bio is a company based in Cambridge (United Kingdom) founded in 2016 by Florian Schuster. bit.bio has raised $266.09 million across 7 funding rounds from investors including Tencent, Charles River Laboratories and Resilience. The company has 52 employees as of December 31, 2020. bit.bio offers products and services including ioCells, ioWild Type Cells, ioDisease Model Cells, and CRISPR-Ready ioCells. bit.bio operates in a competitive market with competitors including Herophilus, Epiloid Biotechnology, Norganoid, Neurxstem and SynaxyS, among others.
- Headquarter Cambridge, United Kingdom
- Employees 52 as on 31 Dec, 2020
- Founders Florian Schuster
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bit Bio Limited
- Date of Incorporation 07 Nov, 2016
- Jurisdiction CAMBRIDGE, CAMBRIDGESHIRE, UNITED KINGDOM
-
Annual Revenue
$467.41 K (USD)-56as on Dec 31, 2021
-
Net Profit
-$36.59 M (USD)-129as on Dec 31, 2021
-
EBITDA
-$40.56 M (USD)-134as on Dec 31, 2021
-
Total Equity Funding
$266.09 M (USD)
in 7 rounds
-
Latest Funding Round
$50 M (USD), Series C
Jan 09, 2026
-
Investors
Tencent
& 10 more
-
Employee Count
52
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of bit.bio
bit.bio offers a comprehensive portfolio of products and services, including ioCells, ioWild Type Cells, ioDisease Model Cells, and CRISPR-Ready ioCells.
Programmed human cells for research and drug discovery applications.
Wild type cells derived from iPSC for various biological studies.
Cells for modeling diseases like ALS and Alzheimer's in research.
Cells ready for CRISPR editing in therapeutic development.
People of bit.bio
Unlock access to complete
Unlock access to complete
Funding Insights of bit.bio
bit.bio has successfully raised a total of $266.09M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in bit.bio
bit.bio has secured backing from 11 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Tencent, Charles River Laboratories and Resilience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified asset management firm and private fund focused on debt and equity investments in climate startups, real estate, and multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
BlueYard Capital is engaged in early-stage technology investments.
|
Locked | Locked | Locked |
Investor details for bit.bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by bit.bio
Investment portfolio details for bit.bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - bit.bio
Detailed financials for bit.bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bit.Bio Comparisons
Peer comparison for bit.bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of bit.bio
bit.bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Herophilus, Epiloid Biotechnology, Norganoid, Neurxstem and SynaxyS, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drug discovery platform to treat neurological disorders
|
|
| Locked | Locked | Locked |
3D cerebral organoid assays are provided for neurological drug testing.
|
|
| Locked | Locked | Locked |
Brain-on-chip solutions are developed to accelerate drug research.
|
|
| Locked | Locked | Locked |
Neural organoid platform is developed from iPSC for brain research.
|
|
| Locked | Locked | Locked |
5D in-vivo brain models for drug discovery are developed.
|
Detailed competitors of bit.bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bit.Bio
Complete news archive for bit.bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about bit.bio
bit.bio was founded in 2016 and raised its 1st funding round 1 year after it was founded.
bit.bio is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
bit.bio is a funded company, having raised a total of $266.09M across 7 funding rounds to date.
As of Dec 31, 2020, the latest employee count at bit.bio is 52.
Annual revenue of bit.bio is $467.41K as on Dec 31, 2021.
bit.bio was founded in 2016 in Cambridge, United Kingdom, focusing on biotechnology for stem cell reprogramming. The opti-ox technology is utilized to activate transcription factors in cells, enabling production of human-induced skeletal myocytes and glutamatergic neurons. These products support research, drug discovery, and cell therapy initiatives in the synthetic biology sector.
bit.bio's top competitors include Herophilus, Epiloid Biotechnology and Neurxstem.
bit.bio offers ioCells, ioWild Type Cells, ioDisease Model Cells, and CRISPR-Ready ioCells.
bit.bio has 11 investors. Key investors include Tencent, Charles River Laboratories, Resilience, M&G, and Arch Venture Partners.
The valuation of bit.bio is $480.58M as of Dec 2021.